Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

Inclusion Criteria * Newborns less than 4 weeks old at diagnosis * Gestational age \>34 weeks * Birth weight 2.2-4kg * Cyanotic heart disease who have had a surgical shunt or a catheterization intervention that is equivalent to a shunt (patent ductus arteriosus stent, right ventricular outflow tract stent). * Baseline hematocrit to be below \<40%. * Completes at least 1 injection in the study by 8 weeks of age. Exclusion Criteria * Infants diagnosed at greater than 4 weeks of age * Gestation \<34 weeks * Birth weight \<2.2 kg or \>4kg * Hematocrit \>40% * Newborns with acyanotic heart disease * Infants with significant co-morbidities: * Renal failure (Creatinine \> 2 standard deviations above age adjusted norm) * Hepatic failure (elevated AST/ALT levels \> 2 standard deviations above age adjusted norm * Hemolytic disease * Hemoglobinopathies (Sickle-cell disease, Thalassemias)